Rosiglitazone reduces body wasting and improves survival in a rat model of cancer cachexia
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patientsSupportive Care in Cancer, 2013
- The role of insulin resistance in the development of muscle wasting during cancer cachexiaJournal of Cachexia, Sarcopenia and Muscle, 2011
- Growth hormone, insulin-like growth factor 1, and insulin signaling-a pharmacological target in body wasting and cachexiaJournal of Cachexia, Sarcopenia and Muscle, 2011
- Insulin Sensitizers May Attenuate Lean Mass Loss in Older Men With DiabetesDiabetes Care, 2011
- Cachexia as a major underestimated and unmet medical need: facts and numbersJournal of Cachexia, Sarcopenia and Muscle, 2010
- Signaling pathways perturbing muscle massCurrent Opinion in Clinical Nutrition and Metabolic Care, 2010
- Insulin Resistance Accelerates Muscle Protein Degradation: Activation of the Ubiquitin-Proteasome Pathway by Defects in Muscle Cell SignalingEndocrinology, 2006
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ)Journal of Biological Chemistry, 1995
- Prognostic effect of weight loss prior tochemotherapy in cancer patientsThe American Journal of Medicine, 1980